Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:03:37 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Z:JNJ - JOHNSON & JOHNSON - https://www.jnj.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
JNJ - Z0.7239.00·240.129.5239.99+2.240.98,273.51,971,720134,085238.96  240.935  237.98239.58  142.2019:59:3019:0015 min RT 2¢

Recent Trades - Last 10 of 134085
Time ETExPriceChangeVolume
19:59:30Z239.701.911
19:58:10Z239.85872.06871
19:56:27Z239.74831.95836
19:56:07Z239.872.081
19:54:07Z239.882.0910
19:53:22Z239.882.0940
19:53:06Z239.882.0930
19:51:13Z239.852.062
19:49:38Z239.852.0650
19:44:57Z239.882.0915

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-06 19:00U:JNJNews ReleaseJohnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
2026-02-02 16:34U:JNJNews ReleaseJohnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
2026-01-27 15:49U:JNJNews ReleaseDARZALEX FASPRO(TM)-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
2026-01-27 08:00U:JNJNews ReleaseJohnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
2026-01-21 06:20U:JNJNews ReleaseJohnson & Johnson reports Q4 and Full-Year 2025 results
2026-01-14 16:30U:JNJNews ReleaseTECVAYLI(TM) monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
2026-01-13 08:00U:JNJNews ReleaseJohnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
2026-01-10 10:00U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
2026-01-08 20:24U:JNJNews ReleaseJohnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
2026-01-07 08:00U:JNJNews ReleaseJohnson & Johnson Submits OTTAVA(TM) Robotic Surgical System to the U.S. Food and Drug Administration
2026-01-06 08:03U:JNJNews ReleaseJohnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
2026-01-02 08:00U:JNJNews ReleaseJohnson & Johnson Announces Quarterly Dividend for First Quarter 2026
2025-12-29 08:00U:JNJNews ReleaseJohnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
2025-12-18 08:00U:JNJNews ReleaseJohnson & Johnson Receives FDA Approval for TRUFILL n-BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
2025-12-17 18:49U:JNJNews ReleaseU.S. FDA Approval of RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE(TM) (lazertinib)
2025-12-15 16:27U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
2025-12-12 20:25U:JNJNews ReleaseU.S. FDA approves AKEEGA(TM) as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
2025-12-09 07:44U:JNJNews ReleaseUnprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI(TM) plus DARZALEX FASPRO(TM) as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
2025-12-08 16:25U:JNJNews ReleaseJohnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-12-06 09:30U:JNJNews ReleaseEarlier use of CARVYKTI(TM) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma